Intraday Info: Abeona Therapeutics Inc (NASDAQ:ABEO) locked on 16/12/2016 at $4.50. It has average volume $277,302 whilst it total volume $570.99k. The company has EPS -0.52 and according to analysts next quarter EPS and next year estimate EPS will -0.13 and -0.56 respectively. And it total income 17.20 million.
Ownership Summary: Abeona Therapeutics Inc has total institutional ownership 17.41% while its total outstanding shares 40 millions that’s value of holdings $31 million.
Active Positions: In the latest year, ABEO 22 holders have raised its positions while it contains total 1,384,821 shares. And the strength of reduced positions holders and held positions holders are 15 and 14 respectively.
New and Sold Out Positions: In ABEO force of new positions holders 10 and it has total shares 666,862. And force of sold out positions holders 8 and it has 647,416 shares.
Comparison with Other Company: The Market Value of ABEO is $179,820 below from AbbVie Inc. market value which is $101M. Current Last Sale of ABEO is $4.5 below from ABBV current last sale which is $62.22.
Abeona Therapeutics Inc. declared financial outcomes for the 1/3 region.
Cash function: cash, cash equivalents and marketable securities as of September 30, 2016 have been $31.2 million, evaluation to $34.3 million as of June 30, 2016. internet cash utilized in operating sports in the 9 Months Ended September 30, 2016 changed into $nine.6 million as evaluation to $7.five million within the same length in 2015, a lift of $2.1 million.
Supplying: On November 1, 2016, we closed an underwritten public offering of 6,000,000 shares of commonplace inventory, at a public providing charge of $7.00 in step with percentage. The gross proceeds to the agency have been $forty two,000,000 million, earlier than deducting the underwriting discounts and commissions and expected presenting fees payable with the aid of the employer.
Sales: revenues have been $184 thousand for the third quarter of 2016, comparison to $285 thousand in the 1/3 sector of 2015. sales consisted of a combination of royalties from advertised merchandise, mainly MuGard®, and popularity of deferred sales related to in advance bills from early license agreements.
Loss in line with proportion: Loss consistent with percentage became $zero.08 for the third area of 2016, assessment to a loss consistent with percentage of $0.19 in the comparable length in 2015.